BACKGROUND Neutrophil counts are a ubiquitous measure of inflammation, but previous studies on their association
T he most numerous type of white blood cell, neutrophils, play a major role in inflammation. Neutrophil count is used routinely as a biomarker of acute infection and inflammation, but not in cardiology. Chronic inflammation contributes to atherosclerosis and cardiovascular diseases (CVD) (1, 2) but, compared with other inflammatory biomarkers such as C-reactive protein (3) and interleukin-6 (4), neutrophil counts have been little studied in relation to long-term CVD risk, even though they are available at scale in clinically collected electronic health record data.
Previous studies have shown that high neutrophil counts are associated with an higher incidence of coronary disease (5) , heart failure (HF) (6) , and stroke (7) (Online Table 1 ). However, these studies were too small to examine thresholds or shape of the associa- (8) . CALIBER has been extensively validated, replicating known prospective associations of CVDs with sex (9), smoking (10), blood pressure (11) , socioeconomic deprivation (12) , and type 2 diabetes (13) .
METHODS
We used the same study cohort as our study on the association of eosinophil and lymphocyte counts with incidence of CVD (14) . The study population was drawn from the CALIBER program (8) 
. CALIBER includes about 4% of the population of England (15) and is representative in terms of age, sex, ethnicity, and mortality (8) .
The study period was January 1998 to March 2010, and individuals were eligible for inclusion when they were at least 30 years of age and had been registered For continuous covariates, we used the most recent value in the year before or up to 1 day after the complete blood count measurement. We also extracted the first measurement after this time window and the last measurement before the time window, along with the timing of these measurements relative to the index date, to use as auxiliary variables for multiple imputation. We also used comorbidity information from hospitalization records. Values are n (%) or median (interquartile range) unless otherwise indicated. *Completeness of recording of continuous variables at any time (as used for imputation) was 98.8% for BP, 90.6% for body mass index, 58.9% for HDL and total cholesterol, and 57.1% for eGFR. Completeness of recording of these variables within 1 year before the index date was 65.4%, 31.3%, 31.6%, and 47.0%, respectively. Diagnoses of comorbid conditions were considered completely recorded (i.e., absence of a diagnosis code was interpreted as absence of the condition).
BMI ¼ body mass index; BP ¼ blood pressure; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular filtration rate; HDL ¼ high-density lipoprotein; IBD ¼ inflammatory bowel disease. Nonspecific coronary artery disease and nonspecific stroke were also included in the analysis as 2 additional endpoints, although they are artefacts of imprecise coding rather than separate disease entities.
Any events occurring after the first cardiovascular presentation were ignored. Endpoint definitions are described in the Online Appendix and phenotyping algorithms are available on the CALIBER web portal (website in the Online Appendix). We analyzed allcause mortality and a composite of all initial cardiovascular presentations as secondary endpoints.
STATISTICAL ANALYSIS. We examined associations of CVD with neutrophil counts initially as a categorical variable. If the shape of the association was found to be linear, we also performed analyses with neutrophil count as a continuous variable. We generated cumulative incidence curves by category of neutrophil count under a competing risks framework.
We used Cox proportional hazards models to estimate cause-specific hazards for each of the 14 cardiovascular endpoints. Hazard ratios (HRs) were adjusted for age (linear and quadratic), sex, age-sex interaction, index of multiple deprivation, ethnicity, smoking status, diabetes, body mass index, systolic blood pressure, estimated glomerular filtration rate, highdensity lipoprotein cholesterol, total cholesterol, For cardiovascular presentations among people without prior cardiovascular disease (CVD), crude cumulative incidence curves are shown for the highest and lowest categories of neutrophil count within the normal range. An artefact of imprecise coding rather than a clinical diagnosis, 'nonspecific coronary disease' was combined with unstable angina. Similarly, nonspecific stroke was combined with ischemic stroke. The plots show that, for myocardial infarction, heart failure, ischemic stroke, peripheral arterial disease (PAD), and abdominal aortic aneurysm, the incidence was greater among people with higher neutrophil counts.
Neutrophil Counts in Cardiovascular Disease Table 3 ). People with neutrophil counts of 6 to 7 Â 10 9 /l (at the upper end of the normal range) had a higher incidence of nonfatal MI, unheralded coronary death, HF, PAD, and abdominal aortic aneurysm compared with people with neutrophil counts of 2 to 3 Â 10 9 /l (Figure 1 ). The risk difference appeared to be greatest for the first few months (Online Table 4 ). Individuals with higher neutrophil counts were relatively more likely to present with unheralded coronary death, HF, or PAD than stable angina (Online Table 5 ).
There were strong, specific associations between neutrophil counts and different initial presentations of CVD (Figure 2 (Figure 2 ).
The associations were stronger in models adjusted only for age and sex (Online Figure 2 ).
There was a strong association of neutrophil count with noncardiovascular death when comparing neutrophil counts of 6 to 7 versus 2 to 3 Â 10 9 /l (HR:
2.01; 95% CI: 1.91 to 2.11), with a higher proportion of deaths due to pneumonia or chronic obstructive pulmonary disease (Online Table 4 ). There was also an association of higher neutrophil count with the composite of CVD (Online Figure 3 ) and all-cause mortality (Online Figure 4) . Neutrophil counts of <2 Â 10 9 /l were associated with greater risk of noncardiovascular death (compared with 2 to 3 Â 10 9 /l: HR: 1.52; 95% CI:
1.41 to 1.63), but were not associated with greater risk of any presentation of CVD (Online Figure 3) .
Because the associations between neutrophil counts and cardiovascular presentations were monotonic and linear, we treated neutrophil count as a linear variable in subsequent modeling. We found stronger associations within the normal range (Online Figure 5 ), but no interaction with smoking
FIGURE 2 Continued
Neutrophil count categories influenced cause-specific adjusted hazard ratios for cardiovascular presentations among people without prior cardiovascular disease (CVD). Hazard ratios were adjusted for age, sex, deprivation, ethnicity, smoking, diabetes, systolic blood pressure (SBP), blood pressure medication, body mass index (BMI), total cholesterol, high-density lipoprotein cholesterol (HDL-C), statin use, estimated glomerular filtration rate (eGFR), atrial fibrillation (AF), autoimmune conditions, inflammatory bowel disease (IBD), chronic obstructive pulmonary disease (COPD), cancer, and acute conditions at the time of blood testing. Shaded ¼ normal range. *p < 0.05; **p < 0.0036; ***p < 0.0001. CI ¼ confidence interval; other abbreviations as in Figure 1 .
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Neutrophil Counts in Cardiovascular Disease status (Online Figure 6 ). Additional adjustment for eosinophil and lymphocyte counts did not alter the estimates (Online Figure 7) .
There was some evidence that associations between neutrophil counts and cardiovascular presentations were stronger for stable compared with acute measurements, particularly for PAD and HF (Figure 3 ).
Associations were further strengthened when we used the mean of 2 consecutive stable neutrophil counts, which were available in 393,543 patients and were taken at a median of 1.4 years apart (IQR: 0.6 to 2.7 years) ( Figure 3 ). There was considerable variability but minimal trend over time between repeat measurements of stable neutrophil counts; the SD of differences between 2 consecutive measurements was 1.67 Â 10 9 /l, the correlation coefficient was 0.568, and the mean rate of change was a decrease of 0.014 per year (95% CI: 0.011 to 0.017) (Online Figure 8) .
We found that hazards were nonproportional for some of the endpoints. We therefore split the followup time by 6 months, and found that neutrophil counts were more strongly associated with HF, unheralded coronary death, and ischemic stroke in the first 6 months (Online Figure 9) . Associations with coronary endpoints, HF, and PAD were stronger among younger patients (Online Figure 10) . The association between neutrophil count and initial presentation with HF was stronger in men than women (HR per 10 9 /l higher neutrophil count: 1.10 vs. 1.07; p ¼ 0.001). There was an association between neutrophil count and initial presentation with transient ischemic attack in women but not men (HR: 1.05 vs. 1.00; p ¼ 0.007) (Online Figure 11) .
DISCUSSION
Neutrophil counts within the range clinicians currently consider normal had strong linear associations with some, but not all, CVDs in a populationbased cohort. We found a greater cumulative incidence of unheralded coronary death, nonfatal MI, HF, PAD, and abdominal aortic aneurysm in patients (7); a key novel finding of our study is the association with PAD and abdominal aortic aneurysm, which has not been reported previously. In contrast with MI, we found that neutrophil count was not associated with a greater incidence of stable or unstable angina. This study's large sample size (>700,000 patients) made it possible to investigate less common CVDs; we showed lack of association with intracerebral hemorrhage and subarachnoid hemorrhage. We also found that associations were stronger among patients with neutrophil counts taken under stable conditions, and when the mean of 2 neutrophil counts was used; this finding provides further evidence for the relevance of a patient's chronic inflammatory state.
TARGETS AND INTERVENTIONS.
Reducing chronic inflammation could be a potential therapeutic avenue in atherosclerotic disease. Our study could not ascertain whether it is circulating neutrophils per se that confer the additional risk or the underlying inflammatory state of which the neutrophil count is a marker (20) . Investigation of causal mechanisms could involve epidemiological studies of upstream determinants of neutrophil counts, such as granulocyte colony-stimulating factor, interleukin-17, and interleukin-23 (21) . Mendelian randomization studies using single nucleotide polymorphisms for genes associated with neutrophil count, such as those identified in the 17q21 region (22) , might also help to evaluate causal relevance.
Colchicine, which has a range of actions on many cell types, including inhibiting microtubule formation in neutrophils, reduced the incidence of acute coronary syndrome and stroke in a trial among patients with stable coronary disease (23) . Trials are underway to investigate whether anti-inflammatory agents such as methotrexate (24) or canakinumab (a human monoclonal antibody against interleukin-1-beta) (25) can prevent CVD events in high-risk individuals.
Smoking causes an elevation of neutrophil counts and is associated more strongly with MI than stable angina (10) Neutrophil Counts in Cardiovascular Disease
